Several studies reported that the expression of EPAS1 is associated with pathogenesis, progression, and prognosis of different cancer types, including renal cell carcinoma [62,63,64], non-small cell lung cancer (NSCLC) [65], hepatocellular carcinoma [66], neuroblastoma [67,68], glioma [69], colorectal carcinoma [35,70,71], esophageal squamous cell carcinoma [59], breast cancer [32,72], and paraganglioma and pheochromocytoma [73,74,75]. Here, EPAS1 is linked to hepatocellular carcinoma.